From: MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
AE | Absolute number and percentage |
---|---|
Constipation | 16 (7.6%) |
Flu-like symptoms | 8 (3.8%) |
Pruritus after injection | 6 (2.8%) |
Fatigue | 5 (2.3%) |
Dizziness | 3 (1.4%) |
Nausea after injection | 3 (1.4%) |
Upper respiratory tract infection | 2 (0.9%) |
Skin rash after injection | 2 (0.9%) |
Lymphadenopathy | 1 (0.4%) |
Serotoninergic syndrome | 1 (0.4%) |
Loss of sexual desire | 1 (0.4%) |
Melanoma | 1 (0.4%) |
Diarrhoea | 1 (0.4%) |
Myalgia | 1 (0.4%) |
Injection site pain | 1 (0.4%) |
Muscular spam | 1 (0.4%) |
Panic attack | 1 (0.4%) |
Palpitations | 1 (0.4%) |
Dehydration | 1 (0.4%) |
Hypermenorrhoea | 1 (0.4%) |
Death | 0 (0%) |
Total | 57 |